{"id":3858,"date":"2021-03-25T11:17:00","date_gmt":"2021-03-25T10:17:00","guid":{"rendered":"http:\/\/leo-foundation.org\/en\/?p=3858"},"modified":"2022-03-22T15:09:17","modified_gmt":"2022-03-22T14:09:17","slug":"annual-report-2020-resilience-and-commitment-in-an-extraordinary-year","status":"publish","type":"post","link":"https:\/\/leo-foundation.org\/en\/2021\/03\/25\/annual-report-2020-resilience-and-commitment-in-an-extraordinary-year\/","title":{"rendered":"Annual Report 2020: Resilience and commitment in an extraordinary year"},"content":{"rendered":"\n
\n
\n
<\/div>\n\n\n
\n \n\n
\n

25 Mar 2021<\/em><\/p>\n\n\n\n

In 2020, the LEO Foundation awarded DKK 72 million to research into the skin and its diseases, LEO Pharma delivered significant strategic progress and accelerated R&D efforts while meeting its operating profit goals and return on the Foundation\u2019s financial investments ended at solid DKK 968 million.<\/strong><\/p>\n\n\n\n

The Annual Report 2020 provides highlights of the LEO Foundation\u2019s three overarching areas: philanthropic activities, engaged ownership and financial investments.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\"\"<\/a>
Click to view the Annual Report 2020<\/figcaption><\/figure>\n\n\n\n
<\/div>\n\n\n\n

Philanthropic activities \u2013 an extraordinary year for science and research<\/strong><\/p>\n\n\n\n

In 2020, the LEO Foundation awarded DKK 72 in independent research grants to researchers around the world dedicated to improving the understanding and treatment of skin diseases. Total payout was DKK 87 million.<\/p>\n\n\n\n

Early in 2020, it became clear that COVID-19 would have a significant impact on the Foundation\u2019s grantees\u2019 activities, which were affected by restrictions, and by research laboratories and universities being closed for months. <\/strong>During the year, the Foundation reached out directly to all grantees with the message that the Foundation would stand by them during these difficult times – not least by offering additional funding to cover delays and other impacts.<\/p>\n\n\n\n

Engaged ownership \u2013 a new partnership to further strengthen LEO Pharma\u2019s leading position in medical dermatology<\/strong><\/p>\n\n\n\n

2020 was also a year where the LEO Foundation developed its engaged ownership of LEO Pharma and paved the way for a new ownership model to provide the best possible conditions for the company\u2019s journey to become a global leader in medical dermatology.<\/p>\n\n\n\n

The process was initiated in mid-2020, and recently, in 2021, the Foundation welcomed Nordic Capital<\/a>, a leading global healthcare private equity investor, as an active minority owner and partner to the Foundation providing the company with the best possible platform to deliver on its ambitious 2030 strategy. Nordic Capital will invest EUR 450 million in LEO Pharma and support the 2030 strategy in partnership with the LEO Foundation who will remain the company\u2019s majority shareholder.<\/p>\n\n\n\n

The partnership with Nordic Capital is a strong confirmation that LEO Pharma is an exceptional company with a valuable heritage in topical dermatology that has clear potential to grow into a leader in innovative therapies.<\/p>\n\n\n\n

Highlights: LEO Pharma delivered on strategic ambitions and showed resilience during COVID-19<\/em><\/strong><\/p>\n\n\n\n